STOCK TITAN

[S-8] KORU Medical Systems, Inc. Employee Benefit Plan Registration

Filing Impact
(No impact)
Filing Sentiment
(Neutral)
Form Type
S-8

KORU Medical Systems, Inc. filed a Form S-8 to register common stock related to equity awards granted to its incoming Chief Commercial Officer. The company granted an Individual Restricted Stock Agreement for 300,000 shares and a Non‑Qualified Stock Option Award covering 600,000 shares, granted July 28, 2025 and August 1, 2025 respectively, each subject to vesting and potential acceleration, to Adam Kalbermatten as an inducement to join as CCO. The registration statement specifically registers the common stock issuable upon exercise of those options and incorporates by reference the company’s annual report and other Exchange Act filings and the description of its common stock. The filing also discloses charter provisions limiting director liability and indemnification provisions, and notes that indemnification for Securities Act liabilities may be unenforceable under SEC precedent.

KORU Medical Systems, Inc. ha presentato un Modulo S-8 per registrare azioni ordinarie relative a premi azionari concessi al suo nuovo Chief Commercial Officer. Alla società è stato concesso un Accordo individuale di azioni ristrette per 300.000 azioni e un Premio in opzioni azionarie non qualificate per 600.000 azioni, concessi rispettivamente il 28 luglio 2025 e il 1° agosto 2025, ciascuno soggetto a maturazione e a possibile accelerazione, ad Adam Kalbermatten come incentivo ad assumere il ruolo di CCO. La dichiarazione di registrazione registra specificamente le azioni ordinarie emettibili all'esercizio di tali opzioni e incorpora per riferimento il rapporto annuale della società, altri documenti ai sensi dell'Exchange Act e la descrizione delle sue azioni ordinarie. Il deposito rivela inoltre disposizioni statutarie che limitano la responsabilità dei direttori e prevedono indennizzi, precisando che l'indennizzo per responsabilità ai sensi della Securities Act potrebbe essere inapplicabile secondo la giurisprudenza della SEC.

KORU Medical Systems, Inc. presentó el Formulario S-8 para registrar acciones ordinarias vinculadas a premios de capital concedidos a su próximo Chief Commercial Officer. La compañía otorgó un Acuerdo individual de acciones restringidas por 300.000 acciones y un Premio de opción sobre acciones no cualificado por 600.000 acciones, concedidos el 28 de julio de 2025 y el 1 de agosto de 2025, respectivamente, cada uno sujeto a períodos de adquisición (vesting) y posible aceleración, a Adam Kalbermatten como incentivo para incorporarse como CCO. La declaración de registro inscribe específicamente las acciones ordinarias emitibles al ejercer esas opciones e incorpora por referencia el informe anual de la compañía y otros documentos presentados conforme al Exchange Act, así como la descripción de sus acciones ordinarias. La presentación también revela disposiciones estatutarias que limitan la responsabilidad de los directores y cláusulas de indemnización, y señala que la indemnización por responsabilidades bajo la Securities Act podría ser inaplicable según la jurisprudencia de la SEC.

KORU Medical Systems, Inc.는 신임 최고상업책임자(CCO)에게 부여된 주식 보상과 관련된 보통주를 등록하기 위해 Form S-8을 제출했습니다. 회사는 Adam Kalbermatten이 CCO로 합류하도록 유인하기 위해 300,000주 대상 개별 제한주 계약600,000주 대상 비자격형 주식매수선택권 수여를 각각 2025년 7월 28일과 2025년 8월 1일에 부여했으며, 각각 베스팅(권리 확정) 및 잠재적 가속화의 대상입니다. 등록서류는 해당 옵션의 행사로 발행될 보통주를 명시적으로 등록하고 회사의 연례보고서 및 기타 Exchange Act 제출서류, 보통주에 대한 설명을 참조로 포함합니다. 제출서에는 이사 책임을 제한하는 정관 조항과 보상(면책) 조항도 공개되어 있으며, SEC 판례에 따르면 Securities Act에 따른 면책은 집행 불가능할 수 있다고 명시되어 있습니다.

KORU Medical Systems, Inc. a déposé un formulaire S-8 pour enregistrer des actions ordinaires liées à des attributions d'actions accordées à son futur Chief Commercial Officer. La société a accordé à Adam Kalbermatten, à titre d'incitation à rejoindre la société en tant que CCO, un accord individuel d'actions restreintes portant sur 300 000 actions et une attribution d'options non qualifiées couvrant 600 000 actions, respectivement accordés le 28 juillet 2025 et le 1er août 2025, chacun sous réserve d'un calendrier d'acquisition (vesting) et d'une éventuelle accélération. La déclaration d'enregistrement enregistre spécifiquement les actions ordinaires susceptibles d'être émises à l'exercice de ces options et incorpore par référence le rapport annuel de la société ainsi que d'autres dépôts au titre de l'Exchange Act et la description de ses actions ordinaires. Le dépôt révèle également des dispositions statutaires limitant la responsabilité des administrateurs et des clauses d'indemnisation, en précisant que l'indemnisation pour des responsabilités au titre du Securities Act pourrait être inapplicable au regard de la jurisprudence de la SEC.

KORU Medical Systems, Inc. hat ein Formular S-8 eingereicht, um Stammaktien zu registrieren, die sich auf Aktienzuwendungen an den künftigen Chief Commercial Officer beziehen. Dem Unternehmen wurden ein einzelner Restricted-Stock-Vertrag über 300.000 Aktien und eine nicht qualifizierte Aktienoptionszuwendung über 600.000 Aktien gewährt, jeweils am 28. Juli 2025 bzw. 1. August 2025, die jeweils einem Vesting-Zeitplan und möglicher Beschleunigung unterliegen, an Adam Kalbermatten als Anreiz zum Eintritt als CCO. Die Registrierungsanmeldung registriert ausdrücklich die bei Ausübung dieser Optionen auszugebenden Stammaktien und bezieht den Jahresbericht des Unternehmens sowie andere Einreichungen nach dem Exchange Act und die Beschreibung der Stammaktien per Verweis ein. Die Einreichung offenbart außerdem Satzungsbestimmungen zur Begrenzung der Haftung von Direktoren und Regelungen zur Entschädigung und weist darauf hin, dass eine Entschädigung für Haftungen nach dem Securities Act nach SEC-Rechtsprechung möglicherweise nicht durchsetzbar ist.

Positive
  • Registration of equity awards to support recruitment of a Chief Commercial Officer (300,000 restricted shares and options covering 600,000 shares).
  • Compliance with SEC rules by incorporating prior Annual Report and Exchange Act filings and including required exhibits and consents.
Negative
  • Charter provisions limit director monetary liability, which the filing notes may discourage shareholder derivative litigation.
  • Indemnification for Securities Act liabilities may be unenforceable under SEC precedent, which the registrant expressly acknowledges.

Insights

TL;DR: The filing documents standard indemnification and director liability limits while noting SEC limits on indemnifying Securities Act liabilities.

The certificate of incorporation and bylaws include a broad limit on director monetary liability and provide for advancement of expenses and indemnification to the maximum extent permitted by Delaware and federal securities law. The filing explicitly recognizes the SEC view that indemnification for liabilities under the Securities Act may be against public policy and unenforceable, and states the company would seek judicial determination if such claims arise. These provisions are routine for corporate charters but are material governance disclosures because they affect directors’ protection and shareholders’ ability to pursue certain claims.

TL;DR: KORU registered equity tied to executive hiring: 300,000 restricted shares plus options for 600,000 shares for the new CCO.

The registration covers 900,000 total shares associated with an inducement package for Adam Kalbermatten, comprising a time‑based restricted stock award and time‑based non‑qualified options. The filing incorporates prior Exchange Act reports and the Form 8‑A description of common stock. Registering these shares is a standard step to permit future issuance upon vesting or exercise; the filing does not disclose vesting schedules, exercise prices, or outstanding share count, so direct capital‑structure impact cannot be quantified from this document alone.

KORU Medical Systems, Inc. ha presentato un Modulo S-8 per registrare azioni ordinarie relative a premi azionari concessi al suo nuovo Chief Commercial Officer. Alla società è stato concesso un Accordo individuale di azioni ristrette per 300.000 azioni e un Premio in opzioni azionarie non qualificate per 600.000 azioni, concessi rispettivamente il 28 luglio 2025 e il 1° agosto 2025, ciascuno soggetto a maturazione e a possibile accelerazione, ad Adam Kalbermatten come incentivo ad assumere il ruolo di CCO. La dichiarazione di registrazione registra specificamente le azioni ordinarie emettibili all'esercizio di tali opzioni e incorpora per riferimento il rapporto annuale della società, altri documenti ai sensi dell'Exchange Act e la descrizione delle sue azioni ordinarie. Il deposito rivela inoltre disposizioni statutarie che limitano la responsabilità dei direttori e prevedono indennizzi, precisando che l'indennizzo per responsabilità ai sensi della Securities Act potrebbe essere inapplicabile secondo la giurisprudenza della SEC.

KORU Medical Systems, Inc. presentó el Formulario S-8 para registrar acciones ordinarias vinculadas a premios de capital concedidos a su próximo Chief Commercial Officer. La compañía otorgó un Acuerdo individual de acciones restringidas por 300.000 acciones y un Premio de opción sobre acciones no cualificado por 600.000 acciones, concedidos el 28 de julio de 2025 y el 1 de agosto de 2025, respectivamente, cada uno sujeto a períodos de adquisición (vesting) y posible aceleración, a Adam Kalbermatten como incentivo para incorporarse como CCO. La declaración de registro inscribe específicamente las acciones ordinarias emitibles al ejercer esas opciones e incorpora por referencia el informe anual de la compañía y otros documentos presentados conforme al Exchange Act, así como la descripción de sus acciones ordinarias. La presentación también revela disposiciones estatutarias que limitan la responsabilidad de los directores y cláusulas de indemnización, y señala que la indemnización por responsabilidades bajo la Securities Act podría ser inaplicable según la jurisprudencia de la SEC.

KORU Medical Systems, Inc.는 신임 최고상업책임자(CCO)에게 부여된 주식 보상과 관련된 보통주를 등록하기 위해 Form S-8을 제출했습니다. 회사는 Adam Kalbermatten이 CCO로 합류하도록 유인하기 위해 300,000주 대상 개별 제한주 계약600,000주 대상 비자격형 주식매수선택권 수여를 각각 2025년 7월 28일과 2025년 8월 1일에 부여했으며, 각각 베스팅(권리 확정) 및 잠재적 가속화의 대상입니다. 등록서류는 해당 옵션의 행사로 발행될 보통주를 명시적으로 등록하고 회사의 연례보고서 및 기타 Exchange Act 제출서류, 보통주에 대한 설명을 참조로 포함합니다. 제출서에는 이사 책임을 제한하는 정관 조항과 보상(면책) 조항도 공개되어 있으며, SEC 판례에 따르면 Securities Act에 따른 면책은 집행 불가능할 수 있다고 명시되어 있습니다.

KORU Medical Systems, Inc. a déposé un formulaire S-8 pour enregistrer des actions ordinaires liées à des attributions d'actions accordées à son futur Chief Commercial Officer. La société a accordé à Adam Kalbermatten, à titre d'incitation à rejoindre la société en tant que CCO, un accord individuel d'actions restreintes portant sur 300 000 actions et une attribution d'options non qualifiées couvrant 600 000 actions, respectivement accordés le 28 juillet 2025 et le 1er août 2025, chacun sous réserve d'un calendrier d'acquisition (vesting) et d'une éventuelle accélération. La déclaration d'enregistrement enregistre spécifiquement les actions ordinaires susceptibles d'être émises à l'exercice de ces options et incorpore par référence le rapport annuel de la société ainsi que d'autres dépôts au titre de l'Exchange Act et la description de ses actions ordinaires. Le dépôt révèle également des dispositions statutaires limitant la responsabilité des administrateurs et des clauses d'indemnisation, en précisant que l'indemnisation pour des responsabilités au titre du Securities Act pourrait être inapplicable au regard de la jurisprudence de la SEC.

KORU Medical Systems, Inc. hat ein Formular S-8 eingereicht, um Stammaktien zu registrieren, die sich auf Aktienzuwendungen an den künftigen Chief Commercial Officer beziehen. Dem Unternehmen wurden ein einzelner Restricted-Stock-Vertrag über 300.000 Aktien und eine nicht qualifizierte Aktienoptionszuwendung über 600.000 Aktien gewährt, jeweils am 28. Juli 2025 bzw. 1. August 2025, die jeweils einem Vesting-Zeitplan und möglicher Beschleunigung unterliegen, an Adam Kalbermatten als Anreiz zum Eintritt als CCO. Die Registrierungsanmeldung registriert ausdrücklich die bei Ausübung dieser Optionen auszugebenden Stammaktien und bezieht den Jahresbericht des Unternehmens sowie andere Einreichungen nach dem Exchange Act und die Beschreibung der Stammaktien per Verweis ein. Die Einreichung offenbart außerdem Satzungsbestimmungen zur Begrenzung der Haftung von Direktoren und Regelungen zur Entschädigung und weist darauf hin, dass eine Entschädigung für Haftungen nach dem Securities Act nach SEC-Rechtsprechung möglicherweise nicht durchsetzbar ist.

 

As filed with the Securities and Exchange Commission on August 12, 2025

 

Registration No. 333-______

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

 

KORU Medical Systems, Inc.
(Exact name of registrant as specified in its charter)

 

 

Delaware   13-3044880
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

 

100 Corporate Drive

Mahwah, NJ

  07430
(Address of Principal Executive Offices)   (Zip Code)

 

 

Individual Non-Qualified Stock Option Award (Time-Based)

Individual Restricted Stock Agreement (Time-Based)

(Full Title of the Plans)

 

 

Copies of all correspondence to:

 

Heather R. Badami, Esq.

Royer Cooper Cohen Braunfeld LLC

Three Logan Square

1717 Arch Street, Suite 4700

Philadelphia, PA 19103

(Name and address of agent for service)

 

(215) 839-1000
(Telephone number, including area code, of agent for service)

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer     Accelerated filer  
Non-accelerated filer       Smaller reporting company
    Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

 


 

EXPLANATORY NOTE

 

Pursuant to an individual Restricted Stock Agreement (time-based) and an individual Non-Qualified Stock Option Award (time-based), the Registrant was granted 300,000 shares of restricted Common Stock and options covering 600,000 shares of Common Stock, respectively, on July 28, 2025 and August 1, 2025, respectively, each subject to vesting and acceleration thereof, to Adam Kalbermatten as a material inducement to Mr. Kalbermatten’s acceptance of employment as the Chief Commercial Officer of the Registrant. This Registration Statement registers the Common Stock issuable upon exercise of such options. The inclusion of such shares herein does not necessarily represent a present intention of Mr. Kalbermatten to sell any or all such shares of Common Stock.

 

 

PART I

 

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

 

As permitted by the rules of the Securities and Exchange Commission (the “Commission”), this Registration Statement omits the information specified in Part I of Form S-8. The documents containing the information specified in Part I will be delivered to the participant as required by Rule 428(b)(1) under the Securities Act of 1933, as amended (the “Securities Act”).

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 3. Incorporation of Documents by Reference.

 

The following documents filed by the Registrant with the Commission pursuant to the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated by reference herein:

 

●     The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 12, 2025;

 

●     All other reports filed by the Registrant pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report referred to in (a) above;

 

●     The description of the Registrant’s common stock set forth in our Form 8-A12B/A filed with the Commission on May 17, 2023.

 

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

Any statement contained herein or in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is or is deemed to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

 

- 2 -


 

Item 4. Description of Securities.

 

Not applicable.

 

Item 5. Interests of Named Experts and Counsel.

 

Not applicable.

 

Item 6. Indemnification of Directors and Officers.

 

Our certificate of incorporation includes a provision that eliminates the personal liability of directors for monetary damages for any breach of fiduciary duty as a director, except where such liability is imposed under the Delaware General Corporation Law (the “DGCL”). The DGCL provides that a corporation may indemnify an individual made a party to a proceeding because he is or was a director against liability incurred in the proceeding unless (i) the act or omission was material to the matter giving rise to the proceeding and was committed in bad faith or was the result of active and deliberate dishonesty; (ii) the director actually received an improper personal benefit; or (iii) in the case of any criminal proceeding, the director had reasonable cause to believe the act or omission was unlawful, provided however, that if the proceeding was by or in the right of the corporation, no indemnification may be made if the director is adjudged liable to the corporation. The Board of Directors of the Registrant (the “Board”) may also indemnify an employee or agent of the corporation who was or is a party to any proceeding by reason of the fact that he is or was an employee or agent of the corporation.

 

Our certificate of incorporation and bylaws provide that, to the maximum extent permitted by Delaware law and the federal securities laws, we must indemnify and, upon request advance, expenses to a director or officer made, or threatened to be made, a party to any action or proceeding (other than a shareholder derivative action) by reason of such person being a director or officer, if such director or officer acted in good faith for a purpose which he or she reasonably believed to be in, or not opposed to, the best interests of the corporation and, in criminal actions or proceedings, in addition, had no reasonable cause to believe that his or her conduct was unlawful. Indemnification would cover reasonable expenses, including attorneys' fees, judgments, fines, amounts paid in settlement.

 

The limitation of liability, indemnification and advancement provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duty. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers.

 

Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

Item 7. Exemption for Registration Claimed.

 

Not applicable.

 

- 3 -


 

Item 8. Exhibits.

 

Exhibit
Number
  Description
     
3.1   Certificate of Incorporation of the Registrant effective May 16, 2023 (incorporated by reference to the Registrant’s Form 8-K, filed with the Securities and Exchange Commission on May 17, 2023).
     
3.2   By-laws of the Registrant dated May 16, 2023 (incorporated by reference to the Registrant’s Form 8-K, filed with the Securities and Exchange Commission on May 17, 2023).
     
4.1   Description of Registrant’s Securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 (incorporated by reference to the Registrant’s Form 8-A12B/A filed with the Commission on May 17, 2023).
     
5.1   Opinion of Royer Cooper Cohen Braunfeld LLC (filed herewith)
     
23.1   Consent of Independent Registered Public Accounting Firm (filed herewith)
     
23.2   Consent of Royer Cooper Cohen Braunfeld LLC (included in Exhibit 5.1)
     
24.1   Power of Attorney (included in signature page)
     
99.1   Non-Qualified Stock Option Award (time-based vesting) between KORU Medical Systems, Inc. and Adam Kalbermatten (incorporated by reference to the Registrant’s Form 10-Q, filed with the Securities and Exchange Commission on August 6, 2025)
     
99.2   Restricted Stock Agreement (time-based vesting) between KORU Medical Systems, Inc. and Adam Kalbermatten (incorporated by reference to the Registrant’s Form 10-Q, filed with the Securities and Exchange Commission on August 6, 2025)
     
107   Filing Fee Table (filed herewith)

 

 Item 9. Undertakings.

 

The undersigned Registrant hereby undertakes:

 

(a)(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

 

(i)          To include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii)         To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the ‘‘Calculation of Registration Fee’’ table in the effective registration statement;

 

(iii)        To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

 

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

 

- 4 -


 

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in this registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

- 5 -


 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Mahwah, State of New Jersey, on August 12, 2025.

 

  KORU Medical Systems, Inc.
   
  By: /s/ Linda Tharby
    Name: Linda Tharby
    Title: Chief Executive Officer

 

We, the undersigned officers and directors of KORU Medical Systems, Inc., hereby severally constitute and appoint Linda Tharby and Thomas Adams, and each of them singly, our true and lawful attorneys with full power to either of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable KORU Medical Systems, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

 

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below by the following persons in the capacities indicated.

 

Signature   Title   Date
         
/s/ Linda Tharby   Chief Executive Officer and Director    
Linda Tharby    (Principal Executive Officer)   August 12, 2025
         
/s/ Thomas Adams   Chief Financial Officer    
Thomas Adams   (Principal Financial Officer and Principal Accounting Officer)   August 12, 2025
         
/s/ R. John Fletcher      
R. John Fletcher   Chairman of the Board   August 12, 2025
         
/s/ Robert Cascella        
Robert A. Cascella   Director   August 12, 2025
         
/s/ Donna French        
Donna French   Director   August 12, 2025
         
/s/ Joseph M. Manko, Jr.        
Joseph M. Manko, Jr.   Director   August 12, 2025
         
/s/ Shar Matin    
Shahriar (Shar) Matin   Director   August 12, 2025
         
/s/ Edward Wholihan      
Edward Wholihan   Director   August 12, 2025

 

- 6 -


FAQ

What did KORU (KRMD) register on Form S-8?

The company registered common stock issuable upon exercise of equity awards granted to Adam Kalbermatten, specifically 300,000 restricted shares and options covering 600,000 shares.

Who received the awards and for what role at KORU?

The awards were granted to Adam Kalbermatten as a material inducement to accept employment as the company’s Chief Commercial Officer.

When were the equity awards granted and are they vested immediately?

The Restricted Stock Agreement was granted on July 28, 2025 and the Option Award on August 1, 2025; both are described as subject to vesting and acceleration.

How many total shares are covered by this registration?

The registration covers a total of 900,000 shares (300,000 restricted shares plus options covering 600,000 shares) issuable upon vesting or exercise.

What exhibits accompany the Form S-8 filing?

Exhibits include the certificate of incorporation, bylaws, description of securities, legal opinion (Exhibit 5.1), auditor consent (Exhibit 23.1), award agreements (99.1 and 99.2 by reference), and the filing fee table (Exhibit 107).
Koru Med Sys

NASDAQ:KRMD

KRMD Rankings

KRMD Latest News

KRMD Latest SEC Filings

KRMD Stock Data

181.70M
42.38M
8.29%
55.73%
2.53%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MAHWAH